Logo

Berndt Modig

May 04, 2018

Centogene announced today that it has appointed Berndt Modig to its supervisory board. Modig currently serves as director and audit committe chair of Axovant Sciences, member of the audit committee of Affimend, and vice chairman of the supervisory board and chair of the audit committee at Kiadis Pharma. In addition, Modig is currently CEO and co-founder of Pharvaris.

Modig previously served as CFO of Prosensa Hodling from Mar. 2010 until its 2015 acquisiotn by BioMarin Pharmaceutical. Prior to Prosensa holding, Modig was CFO at Jerini AG. Modig has also held a variety of senior management positions at Surplex AG, Hayward Industrial Products, Agra Industrial, and Price Waterhouse. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.